SEARCH:   Advanced

Blood, 15 August 2006, Vol. 108, No. 4, pp. 1381-1387. Prepublished online as a Blood First Edition Paper on April 18, 2006; DOI 10.1182/blood-2005-10-4043. This Article Full Text Full Text (PDF) Supplemental Figure All Versions of this Article: 2005-10-4043v1 108/4/1381    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tomosugi, N. Articles by Ishikawa, I. Search for Related Content PubMed PubMed Citation Articles by Tomosugi, N. Articles by Ishikawa, I. Related Collections Red Cells Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  RED CELLS Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System Naohisa Tomosugi, Hiroshi Kawabata, Rumi Wakatabe, Masato Higuchi, Hideki Yamaya, Hisanori Umehara, and Isao Ishikawa From the Division of Nephrology, Department of Internal Medicine, Kanazawa Medical University, Ishikawa; the Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University; the Ciphergen Biosystems, Biomarker Discovery Center, Yokohama; the Department of Toxin, Chugai Pharma, Shizuoka; and the Division of Hematology and Immunology, Department of Internal Medicine, Kanazawa Medical University, Ishikawa, Japan. Hepcidin, a key regulator of iron metabolism, is expressed in the liver, distributed in blood, and excreted in urine. However, to date, no reliable and practical method for measuring the bioactive form of hepcidin in serum has been developed. Here, we used surface-enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF MS) to analyze the distinctive serum proteomic patterns of patients receiving hemodialysis. In the range of 1000 to 15 000 m/z, we found 3 peptides at 2192, 2789, and 2851 m/z that showed a significant correlation with the serum ferritin levels. The molecular sizes of peptides at 2192 and 2789 m/z matched with the reported sizes of hepcidin-20 and -25, respectively, and the serum peptide at 2789 m/z was identified as hepcidin-25 by collision-induced dissociation tandem MS. By using SELDI-TOF MS, we developed a semiquantitative assay for hepcidin-25. In this assay, the level of serum hepcidin-25 correlated well with levels of serum ferritin and serum interleukin-6. Hepcidin-25 was found to accumulate in the serum of patients receiving hemodialysis; this could contribute to the pathogenesis of renal anemia by decreasing the available iron for hematopoiesis. Thus, SELDI-TOF MS would be a clinically useful tool to detect and semiquantify bioactive hepcidin in serum. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. P.E. Peters, C. M.M. Laarakkers, D. W. Swinkels, and J. F.M. Wetzels Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate Nephrol. Dial. Transplant., October 23, 2009; (2009) gfp546v1. [Abstract] [Full Text] [PDF] L. Valenti, D. Girelli, G. F. Valenti, A. Castagna, G. Como, N. Campostrini, R. Rametta, P. Dongiovanni, P. Messa, and S. Fargion HFE Mutations Modulate the Effect of Iron on Serum Hepcidin-25 in Chronic Hemodialysis Patients Clin. J. Am. Soc. Nephrol., August 1, 2009; 4(8): 1331 - 1337. [Abstract] [Full Text] [PDF] B. Young and J. Zaritsky Hepcidin for Clinicians Clin. J. Am. Soc. Nephrol., August 1, 2009; 4(8): 1384 - 1387. [Abstract] [Full Text] [PDF] J. Zaritsky, B. Young, H.-J. Wang, M. Westerman, G. Olbina, E. Nemeth, T. Ganz, S. Rivera, A. R. Nissenson, and I. B. Salusky Hepcidin--A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., June 1, 2009; 4(6): 1051 - 1056. [Abstract] [Full Text] [PDF] J. Malyszko Hepcidin Assays: Ironing Out Some Details Clin. J. Am. Soc. Nephrol., June 1, 2009; 4(6): 1015 - 1016. [Full Text] [PDF] M. F Young, R. P Glahn, M. Ariza-Nieto, J. Inglis, G. Olbina, M. Westerman, and K. O O'Brien Serum hepcidin is significantly associated with iron absorption from food and supplemental sources in healthy young women Am. J. Clinical Nutrition, February 1, 2009; 89(2): 533 - 538. [Abstract] [Full Text] [PDF] A. L. M. de Francisco, P. Stenvinkel, and S. Vaulont Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness NDT Plus, January 1, 2009; 2(suppl_1): i18 - i26. [Abstract] [Full Text] [PDF] T. Ganz, G. Olbina, D. Girelli, E. Nemeth, and M. Westerman Immunoassay for human serum hepcidin Blood, November 15, 2008; 112(10): 4292 - 4297. [Abstract] [Full Text] [PDF] J. F. Collins, M. Wessling-Resnick, and M. D. Knutson Hepcidin Regulation of Iron Transport J. Nutr., November 1, 2008; 138(11): 2284 - 2288. [Abstract] [Full Text] [PDF] J. Kanda, C. Mizumoto, H. Kawabata, H. Tsuchida, N. Tomosugi, K. Matsuo, and T. Uchiyama Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation Haematologica, October 1, 2008; 93(10): 1550 - 1554. [Abstract] [Full Text] [PDF] D. W. Swinkels and J. F. M. Wetzels Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2450 - 2453. [Full Text] [PDF] E. H.J.M. Kemna, H. Tjalsma, H. L. Willems, and D. W. Swinkels Hepcidin: from discovery to differential diagnosis Haematologica, January 1, 2008; 93(1): 90 - 97. [Abstract] [Full Text] [PDF] A. T. Murphy, D. R. Witcher, P. Luan, and V. J. Wroblewski Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry Blood, August 1, 2007; 110(3): 1048 - 1054. [Abstract] [Full Text] [PDF] H. Kawabata, N. Tomosugi, J. Kanda, Y. Tanaka, K. Yoshizaki, and T. Uchiyama Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease Haematologica, June 1, 2007; 92(6): 857 - 858. [Abstract] [Full Text] [PDF] E. H.J.M. Kemna, H. Tjalsma, V. N. Podust, and D. W. Swinkels Mass Spectrometry-Based Hepcidin Measurements in Serum and Urine: Analytical Aspects and Clinical Implications Clin. Chem., April 1, 2007; 53(4): 620 - 628. [Abstract] [Full Text] [PDF] T. Ganz Molecular Control of Iron Transport J. Am. Soc. Nephrol., February 1, 2007; 18(2): 394 - 400. [Abstract] [Full Text] [PDF] J. Himmelfarb Iron Regulation J. Am. Soc. Nephrol., February 1, 2007; 18(2): 379 - 381. [Full Text] [PDF] T. Ganz Hepcidin and Its Role in Regulating Systemic Iron Metabolism Hematology, January 1, 2006; 2006(1): 29 - 35. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020